الفهرس Only 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
HCV is a major cause of CHC. Egypt has the highest rate of HCV infection (genotype 4) in the world. IL-21R gene polymorphism is recently studied as pretreatment predictor in CHC patients treated with peg-INFplus ribavirin. In this study, we focus on evaluate of blood IL-21R gene polymorphism in CHC genotype 4 Egyptian patients and investigate it is benefit as a pretreatment predictor of antiviral response. This prospective study was carried out on 80 chronic hepatitis C (CHC) genotype 4 patients. All 80 CHC patients were subjected to treatment with pegylated Interferon alpha-2a (180 mcg subcutaneously once weekly for 48 weeks) plus ribavirin (1000-1200 mg/day according to body weight less or greater than 75 Kg) from January 2014 to January 2015. At the end of treatment our patients were divided into two groups; responders (44 patients) and non-responders (36 patients), all patients were subjected to different biochemical and IL-21R genotyping analyses. In conclusion, patients with IL-21R rs3093390 CC genotype had a higher sustained virological response to peg-INF treatment than those with non-CC genotypes